DNA synthesis machinery and DNA

The DNA synthesis machinery and DNA represent a fundamental therapeutic target complex responsible for the replication and maintenance of the genetic blueprint. This machinery comprises a coordinated assembly of enzymes, including DNA polymerases, helicases, and topoisomerases, which work in concert to ensure high-fidelity duplication of the genome during the S-phase of the cell cycle (Alberts B, et al., Molecular Biology of the Cell, 2002). DNA itself serves as a direct target for various chemical agents that induce structural damage or cross-linking, thereby preventing replication and transcription (NCI, Alkylating Agents, 2023). In oncology, drugs targeting this complex, such as antimetabolites and alkylating agents, exploit the rapid proliferation of cancer cells to induce apoptosis (StatPearls, Antimetabolites, 2023). In infectious diseases, selective inhibitors of bacterial or viral DNA synthesis machinery, such as fluoroquinolones or nucleoside analogs, provide a basis for antimicrobial and antiviral therapy (PubMed, PMC7120343). However, because these processes are also essential for normal cell turnover, therapies targeting DNA synthesis often result in significant side effects like myelosuppression and mucositis (Goodman & Gilman's, 2018).

Other names

DNA replication machineryReplisomeDNA synthesis apparatusDNA replication complex

Mechanisms include the inhibition of nucleotide precursor synthesis (antimetabolites), direct chemical modification of DNA leading to cross-links or strand breaks (alkylating agents and platinum compounds), physical insertion between base pairs (intercalators), and the inhibition of enzymes required for unwinding, copying, or re-sealing DNA (polymerase and topoisomerase inhibitors) (StatPearls, 2023; NCI, 2023).